连续两次发生集群头痛的患者用加尔坎祖马布进行预防性治疗:一项多中心观察性研究
Yooha Hong1, Mi-Kyoung Kang1, Heui-Soo Moon2
1Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Keun Jae Bong-gil 7, Hwaseong, Gyeonggi-do, 18450, Republic of Korea.
The journal of headache and pain
|October 10, 2023
概括
加尔坎祖马布 (Galcanezumab) 是一种针对偶发性集群头痛的预防疗法,在连续的集群头痛中表现出一致的疗效. 这种治疗可以减少头痛的频率和强度,而没有显著的不良影响,为管理经常性集群头痛提供了潜在的选择.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 头痛 医学 医学 医学
背景情况:
- 集群头痛是一种严重的,致残的初级头痛障碍.
- 加尔坎祖马布 (Galcanezumab) 是一种与卡尔西托尼基因相关的单克隆抗体,是治疗偶发性集群头痛的预防疗法.
- 在连续的集群发作中,galcanezumab的有效性一致性需要评估.
研究的目的:
- 评估240毫克的加尔坎祖马布治疗连续集群头痛患者连续集群头痛的疗效和安全性.
- 为了评估galcanezumab在多个集群时期的预防作用的一致性.
主要方法:
- 一项观察性研究涉及患有偶发性集群头痛的患者,接受两次加尔坎祖马布治疗.
- 通过比较头痛频率,几天,强度和每次集群发作前后注射加尔坎祖马布的副作用来分析有效性和安全性.
- 配对的t测试被用来进行重复测量的统计比较.
主要成果:
- 86%和64%的患者在第一个和第二个集群发作期间,在第3周的每日头痛频率减少了≥50%.
- 在集群发作之间没有观察到严重的不良反应或不良影响的显著差异.
- 在集群前期间,两名患者接受了第二剂加尔卡涅苏马布,防止了典型的集群头痛发作.
结论:
- 加尔坎祖马布 (Galcanezumab) 证明了其作为预防性治疗的潜在有效性,用于随后发生的集群发作中的偶发性集群头痛.
- 患者可能会从早期重新治疗加尔坎祖马布 (galcanezumab) 以后的集群发作中受益,可能避免过渡疗法.
相关概念视频
Open Angle Glaucoma: Treatment
471
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
471
Angle Closure Glaucoma: Treatment
540
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
540
Parkinson's Disease: Treatment
283
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
283
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
136
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
136
Hypoglycemia and Glucagon
274
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
274
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
173
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
173


